Short interest spike weighs
NTLA is dropping sharply on elevated short interest hitting 40%, which dwarfs the modestly positive FDA news for its lead drug, Lonvo-z.
Sources: https://www.tradingview.com/news/tradingview:4c415af81fd57:0-intellia-announces-fda-acceptance-of-bla-for-lonvo-z-with-pdufa-date-march-10/, https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleas
Previous verdicts for NTLA
- AI Search: Barclays Underweight Initiation Pressures Intellia Therapeutics — 2026-10-06
- Commercial Caution — 2026-09-15
- Cathie Wood adds NTLA — 2026-09-14
- Short interest spike weighs — 2026-09-09
- Debt deal lifts stock — 2026-09-04
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works